Discovery of anti-DENV Antibodies Using Artificial Intelligence (360G-Wellcome-215840_Z_19_Z)
Dengue virus (DENV) is a viral pathogen of global health significance: in 390 million cases worldwide, 96 million exhibited clinical symptoms and resulted in 21 thousand deaths. Currently, there are no therapeutic treatments against DENV. DENV is composed of four similar but serologically different viruses (DENV 1-4). Cross-reactive, neutralizing antibodies to all four DENV serotypes may provide an effective passive treatment against severe DENV disease. A large number of potentially successful antibody candidates remain undiscovered due to the complexity of the natural immune response (theoretical antibody repertoire of 10140 potential antibodies). We aim to apply network analyses and machine learning to investigate large amounts of raw high-throughput sequence data from antibody repertoires, resulting in detection of rare, under-represented DENV-specific antibodies. This project aims to discover and develop new neutralizing antibodies for therapeutic treatment of dengue infection and inform vaccine design.
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
| Amount Awarded | 658570 |
| Applicant Surname | Miho |
| Approval Committee | Innovator Awards Advisory Group |
| Award Date | 2019-02-28T00:00:00+00:00 |
| Financial Year | 2018/19 |
| Grant Programme: Title | Innovator Award: Digital Technologies |
| Internal ID | 215840/Z/19/Z |
| Lead Applicant | Prof Enkelejda Miho |
| Partnership Value | 658570 |
| Planned Dates: End Date | 2022-04-22T00:00:00+00:00 |
| Planned Dates: Start Date | 2019-10-01T00:00:00+00:00 |
| Recipient Org: Country | Switzerland |
| Region | International |